Descripción del proyecto
Actuar sobre los defectos multiorgánicos como forma de tratamiento de la atrofia muscular espinal
La atrofia muscular espinal (AME) es un trastorno neuromotor causado por la reducción de la concentración de la proteína de supervivencia de las motoneuronas (SMN). La proteína SMN se expresa de forma ubicua en el sistema nervioso central (SNC) y los órganos periféricos. La restitución de la concentración de proteínas SMN en el SNC constituye una estrategia potente que ha dado lugar a la aprobación de terapias para su uso clínico. El proyecto financiado con fondos europeos SMABEYOND tiene por objeto investigar el papel de la proteína SMN en los órganos periféricos y determinar los defectos intrínsecos observados en pacientes con AME. El fin último es desarrollar modelos patológicos derivados de pacientes con AME y evaluar el efecto terapéutico sobe los órganos periféricos de la terapia sistémica para la AME.
Objetivo
Spinal Muscular Atrophy (SMA) is a monogenic motoneuron disease with a neuromuscular phenotype resulting in infant death in severe cases. Besides motoneurons in the central nervous system (CNS), there is growing evidence of an involvement of peripheral organs. SMA is caused by reduced Survival of Motoneuron (SMN) protein levels and SMN is ubiquitously expressed. Therefore, SMA patients show reduced SMN levels also in peripheral organs. A restoration of SMN levels in the CNS is a potent therapeutic strategy which led to the approval of two different compounds: Spinraza is an antisense oligonucleotide which increases SMN mRNA, Zolgensma is an adeno-associated virus increasing expression of SMN. However, both strategies focus on the restoration of CNS SMN levels without a sustainable effect on peripheral organs. In 2020, approval of a third drug, Risdiplam, a systemic SMN enhancer, is expected. Although patients greatly benefit from a treatment of the neuromuscular phenotype they face a precarious future: there is no comprehensive landscape of vulnerable organs and no approved treatment for the periphery. We will analyze intrinsic defects in peripheral organs (WP1), evaluate the organ specific molecular and cellular functions of the SMN protein in relevant organs (WP2), and translate these findings to SMA patient derived models, which we will treat with a systemic SMA drug currently under clinical evaluation (WP3). The SMA field involves stakeholders, which allow early stage researchers to personally interact with basic scientists, clinicians, pharmaceutical companies and patient organizations. For our training network, we will combine this vertical integration with a broad perspective on multiple organ systems in SMA. The training strategy assures career options and employability of early stage researchers beyond the SMA field. We will go beyond the motoneuron and identify organs, mechanisms and molecules that could be targets for the peripheral aspects of SMA.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinador
76185 Karlsruhe
Alemania